The FDA has raised concerns about unapproved GLP-1 drugs, with retatrutide named in Polskie Radio's coverage. Details are thin, so tap through for the full story.
Recap by typeshit. Full story at www.polskieradio.pl.
Lilly's retatrutide is still in development with no FDA approval, yet CBS investigators found vials labeled 'reta' easy to buy across the internet and in shops.
A systematic review cited by Dr. Axe found human safety data on BPC-157 comes from just 30 people, a thin base for a widely used peptide.
A short post from the endocrinologist pushing back on headlines tying the eye condition to GLP-1 drugs, urging people to look at the data.
A brief post notes growing concern over reports of serious eye problems in people taking Ozempic and similar drugs, while research into the link continues.
A general explainer post contrasts the receptor activity of the two incretin drugs used in metabolic care. Little detail is available beyond the title.
Polish pharmacy platform GdziePoLek says, citing the manufacturer, that the first Oral Wegovy shipment should arrive soon. No exact launch date is set yet.
Loading…